The global nuclear medicine market size was valued at USD 6.5 billion in 2020 and is anticipated to expand at a CAGR of 9.4% during the forecast period, 2021-2028. The growth of the market is attributed to the increasing occurrences of cancer to which the best treatment available to all patients is nuclear medicine sciences and diagnostics.
Nuclear medicine is the medical specialty that involves the application of multiple radioactive substances in the treatment and diagnostics of various complicated diseases and disorders. From nuclear medicine, a large variety of studies have been introduced such as the endoradiology where in the study of radiation emitting within the body over radiation from external sources such as X-rays are being identified from the patient’s body.
Nuclear medicine is very similar to radiology, the only key difference being the focus of emphasis is on the function of the human body alone and not on their imaging anatomy. In other words, nuclear medicine studies the body functions with respect to any body, be it disabled or disfigured.
Nuclear medicine has mainly found applications in diagnostic medical imaging and hybrid scanning techniques. According to the World Health Organization or the WHO, there has been 9.6 million deaths owing to irregular treatment of cancer. With nuclear medical diagnostics, the WHO believes that over 80% could have been saved and reported healthy. There has also been a significant rise in the cardiovascular diseases, as per the WHO report which states that more than 17.8 million have died and will increase north to 23 million by 2030.
The COVID-19 pandemic has reduced the growth of the global nuclear medicine market initially. Researchers and scientists were not able to recognize the co-relation between the coronavirus and nuclear medicine. However, upon further research, they were able to identify that nuclear medicine along with the latest radiopharmaceuticals can help produce a permanent cure for the coronavirus. This steered to hospitals, clinics, and healthcare laboratories to focus more on the development of nuclear medicine radiopharmaceuticals for the prevention and treatment of diseases and this led to its market growth in the later stages of the COVID-19 pandemic.
Nuclear Medicine Market Trends, Drivers, Restraints, and Opportunities
- Increase in occurrences of cardiovascular diseases which can be treated by nuclear medical diagnostics is the primary reason for the projection of boosting the global nuclear medicine market growth during the forecast period, 2021-2028.
- There has been a significant increase in the research and development activities leading to technological advancement of nuclear medicine which can become a major factor boosting the market growth. The introduction of radiopharmaceuticals used in various techniques including molecular imaging, a method that involves to act a biomarkers for the specific molecular processes required for the determination of onset and progress of the disease.
- High prices for the development of nuclear medicine and high cost of services from the company’s perspective is anticipated to hinder the global nuclear medicine market growth. This becomes extremely difficult to function in developing countries such as India, South Africa and Brazil where there is limited healthcare infrastructure.
- Nuclear Medicine needs to be diagnosed on favorable environments and not all patients can be able to undergo this treatment. There could be the possibility of patients being allergic to radiotherapy methods at close range. This can hamper the nuclear medicine market growth.
- R&D activities along with studies have shown that radiotherapy under the influence of nuclear medicine can be used for the treatment for complicated diseases including thyroid-related diseases, bone diseases, neurological diseases, and respiratory diseases. In July 2019, French investigators published their findings upon the demonstration of the hafnium oxide nanoparticle or the NBTXR3 to act as an enhancer for radio waves used for improving the response for soft-tissue sarcoma by using radiotherapy.
Scope of Nuclear Medicine Market Report
The report on the global nuclear medicine market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Nuclear Medicine Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Products (Diagnostic Products [SPECT {TC-99m, TL-201, GA-67, I-123, and Other SPECT Products} and PET {F-18, SR-82/RB-82, and Other PET Products}] and Therapeutic Products [Alpha Emitters {RA-223 and Other Alpha Emitters}, Beta Emitters {I-131, Y-90, SM-153, Re-186, Lu-117, and Other Beta Emitters}, and Brachytherapy {Cesium-131, Iodine-125, Palladium-103, Iridium-192, and Other Brachytherapy Products}]) and Applications (Cardiology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Nordion Inc; Eckert & Ziegler Group; GE Healthcare; Bracco Imaging S.p.A; Department of Atomic Energy; and Australian Nuclear Science and Technology Organization (ANSTO)
|
Nuclear Medicine Market Segment Insights
Product Segment Analysis
Based on products, the global nuclear medicine market is bifurcated into diagnostic products and therapeutic products. The diagnostic products are further bifurcated into SPECT and PET. The SPECT is again divided into TC-99m, TL-201, GA-67, I-123, and other SPECT Products. The PET products are divided into F-18, SR-82/RB-82, and other PET products. The therapeutic products are divided into Alpha emitters, Beta emitters, and Brachytherapy.
The Alpha emitters are further bifurcated into RA-223 and other Alpha emitters. The Beta emitters are divided into I-131, Y-90, SM-153, Re-186, Lu-117, and other Beta emitters. The Brachytherapy is divided into Cesium-131, Iodine-125, Palladium-103, Iridium-192, and other Brachytherapy products. The therapeutic segment is expected to constitute the major share of the market in 2019. Beta emitters in the therapeutic segment has the methodology involving the least damage to surrounding cells, travels long distances, and operate on low energy levels.
Meanwhile the diagnostic segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The major reason attributing to this market growth is the cost-effectivity, early diagnosis, high sensitivity, non-evasiveness, and easy to handle towards abnormalities in any structure or organ structure.
Application Segment Analysis
On the basis of applications, the global nuclear medicine market is divided into cardiology, oncology, thyroid, lymphoma, bone metastasis, endocrine tumor, and others. The cardiology segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the low cost of procedures along with the high adoption rates.
Meanwhile the thyroid segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The latest techniques and technological advancements have been focused primarily upon the thyroid segment.
Regional Analysis
On the basis of regions, the global Nuclear Medicine market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to constitute the largest share in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology.
The demand of nuclear medicine is increasing rapidly in this region due to the presence of the major market players in the market, an advantage other regions do not have. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2021-2028, as they have prioritized the cost-efficiency perspective of nuclear medicine combined with their growing population.
Segments
The global Nuclear Medicine market size has been segmented in terms of
Products
- Diagnostic Products
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Other SPECT Products
- PET
- F-18
- SR-82/RB-82
- Other PET Products
- Therapeutic Products
- Alpha Emitters
- RA-223
- Other Alpha Emitters
- Beta Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-117
- Other Beta Emitters
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Other Brachytherapy Products
Applications
- Cardiology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Nordion Inc
- Eckert & Ziegler Group
- GE Healthcare
- Bracco Imaging S.p.A
- Department of Atomic Energy
- Australian Nuclear Science and Technology Organization (ANSTO)
Competitive Landscape
Major players competing in the global nuclear medicine market are Nordion Inc; Eckert & Ziegler Group; GE Healthcare; Bracco Imaging S.p.A; Department of Atomic Energy; and Australian Nuclear Science and Technology Organization (ANSTO). These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Nordion Inc purchased Cobalt-60 for their distribution unit in Europe from the Board of Radiation and Isotope Technology or the BRIT in April 2019.
Request For Customization
Enquiry Before Buying
Speak With Analyst
